Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure

References

• The CONSENSUS Trial Study GroupEffects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)N Engl J Med1987316142914352883575
   PubMed Web of Science ®Google Scholar
• The SOLVD InvestigatorsEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med19913252933022057034
   PubMed Web of Science ®Google Scholar
• PackerMBristowMRCohnJNfor the US Carvedilol Heart Failure Study GroupThe effect of carvedilol on morbidity and mortality in patients with chronic heart failureN Engl J Med1996334134913558614419
   PubMed Web of Science ®Google Scholar
• CIBIS II Investigators and CommitteesThe Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trialLancet199935391310023943
   PubMed Web of Science ®Google Scholar
• Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Study GroupEffect of metoprolol CR/XL in chronic heart failureLancet19993532001200710376614
   PubMed Web of Science ®Google Scholar
• PackerMCoatsAJFowlerMBfor the Carvedilol Prospective Randomized Cumulative Survival Study GroupEffect of carvedilol on survival in severe chronic heart failureN Engl J Med20013441651165811386263
   PubMed Web of Science ®Google Scholar
• HuntSAAbrahamWTChinMH2009Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung TransplantationCirculation2009119e391e47919324966
   PubMed Web of Science ®Google Scholar
• European Society of CardiologyHeart Failure Association of the ESC (HFA)European Society of Intensive Care Medicine (ESICM)ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008Eur J Heart Fail20081093398918826876
   PubMed Web of Science ®Google Scholar
• Heart Failure Society of AmericaExecutive summary: HFSA 2006 Comprehensive Heart Failure Practice GuidelineJ Card Fail200612103816500578
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGfor the Valsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med20013451667167511759645
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKfor the CHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet200336276777113678869
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGGlazerRDRationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failureJ Card Fail1999515516010404355
   PubMed Web of Science ®Google Scholar
• BaruchLAnandICohenISfor the Vasodilator Heart Failure Trial (V-HeFT) Study GroupAugmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failureCirculation1999992658266410338459
   PubMed Web of Science ®Google Scholar
• GrubbANymanUBjörkJSimple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for childrenClin Chem2005511420143115961546
   PubMed Web of Science ®Google Scholar
• OparilSDykeSHarrisFThe efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertensionClin Ther1996187978108930424
   PubMed Web of Science ®Google Scholar
• PoolJOparilSHednerTDose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blockerClin Ther199820110611149916605
   PubMed Web of Science ®Google Scholar
• BlackHRGraffAShuteDValsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinoprilJ Hum Hypertens1997114834899322828
   PubMed Web of Science ®Google Scholar
• WillenheimerRHelmersCPantevEfor the Heart Failure Valsartan Exercise Capacity Evaluation Study GroupSafety and efficacy of valsartan versus enalapril in heart failure patientsInt J Cardiol20028526127012208593
   PubMed Web of Science ®Google Scholar
• De TommasiEIacovielloMRomitoRComparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failureAm Heart J2003146854859
   Web of Science ®Google Scholar
• WeinbergMSWeinbergAJZappeDHEffectively targeting the renin-angiotensin system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin converting enzyme-inhibitorsJ Renin Angiotensin Aldosterone Syst2000121723311881029
   PubMedGoogle Scholar
• JacobsenPAndersenSJensenBRParvingHHAdditive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathyJ Am Soc Nephrol20031499299912660333
   PubMed Web of Science ®Google Scholar
• McMurrayJCohen-SolalADietzRPractical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practiceEur J Heart Fail2005771071216087129
   PubMed Web of Science ®Google Scholar
• LatifFTandonSObelenieneRAngiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjectsJ Card Fail2001726526811561228
   PubMed Web of Science ®Google Scholar
• MaillardMPWürznerGNussbergerJCentenoCBurnierMBrunnerHRComparative angiotensin II receptor blockade in healthy volunteers: the importance of dosingClin Pharmacol Ther200271687611823759
   PubMed Web of Science ®Google Scholar
• LatiniRMassonSAnandIfor the Valsartan Heart Failure Trial InvestigatorsEffects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)Circulation20021062454245812417542
   PubMed Web of Science ®Google Scholar